Harmony Biosciences shares are trading lower after the company reported topline data from its Phase 3 INTUNE study of pitolisant for IH, noting no statistically significant difference was observed between pitolisant and placebo on ESS.
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences reported no statistically significant difference between pitolisant and placebo in its Phase 3 INTUNE study for IH. This has led to a decrease in the company's share price.
October 13, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harmony Biosciences' stock price is trading lower due to the disappointing results from its Phase 3 INTUNE study.
The company's stock price is directly impacted by the results of its clinical trials. The lack of significant difference between pitolisant and placebo in the Phase 3 INTUNE study indicates that the drug may not be as effective as hoped, which negatively impacts investor sentiment and leads to a decrease in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100